Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1893 participants.

Also called NCT01755520

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,893 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01755520
  • EudraCT 2012-003630-16
Other papers using this trial's data
  • Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial European heart journal, 2019-08-01 DOI, PubMed 31145798

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Germany, Switzerland (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01755520. Randomized; quadruple masking; primary purpose treatment. Start 2013-04-24 (registry gives no type); primary completion 2018-05-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG
Acronym
TiCAB
Condition
Stable Angina
Condition
Acute Coronary Syndrome
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Aspirin
Intervention (Drug)
Placebo - Ticagrelor
Intervention (Drug)
Placebo - Aspirin
Lead sponsor
Deutsches Herzzentrum Muenchen (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01755520
Content hash
607b2f3427771a18557ad32a07a0682afdd4f3f33bdd9f32aff18363870a25da